Market Overview

UPDATE: Allergan Confirms Receipt of Unsolicited Proposal from Valeant, Will Review Offer

Share:
Related AGN
Buyback ETF Steady As Repurchases Decline
Teva's Stock Inches Higher Amid Cost-Cutting Plan
The Vetr community has downgraded $AGN to 3-Stars (Vetr)
Related VRX
What Happens To A Stock When An Activist Liquidates A Position?
Gadfly's Nisen: Valeant's 'Financial Wizardry' Doesn't Change The Long-Term Outlook
Behind the Bill Ackman Controversies (GuruFocus)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today confirmed that it has received an unsolicited proposal from Valeant Pharmaceuticals International, Inc. (“Valeant”) to acquire all of the outstanding shares of the Company for a combination of 0.83 of Valeant common shares and $48.30 in cash per share of common stock of the Company (the “Proposal”).

The Allergan Board of Directors, in consultation with its financial and legal advisors, will carefully review and consider the Proposal and pursue the course of action that it believes is in the best interests of the Company's stockholders. The Company's stockholders do not need to take any action at this time.

Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the Company and Latham & Watkins is serving as legal counsel to the Company.

Posted-In: News M&A Press Releases

 

Related Articles (AGN + VRX)

View Comments and Join the Discussion!